AI Stock Memo: DBVT - DBV - RankAlpha

DBVT

Rating buyAI Memo

DBV

As of 2026-01-20/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-20 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Regulatory interaction / filing milestone • 2026-12-31

Expected move: +85%

Biggest risk

Negative or ambiguous results, regulatory setbacks, or cash/runway issues leading to dilution and valuation compressing toward analyst low.

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Successful near-term clinical readout plus a partnership or expedited regulatory progress drives re-rating toward upper analyst range and rapid revenue ramp.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-20

Base target

$35

p=60%

Bull target

$46

p=20%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Interim clinical readout for lead EPIT program
Commercial partnerships and early launch progress
Successful near-term clinical readout plus a partnership or expedited regulatory progress drives re-rating toward upper analyst range and rapid revenue ramp.

BearKey bullets

Cash‑runway shortfall leading to dilutive financing
Negative pivotal clinical readout or safety signal
Poor payer coverage or slow commercial uptake

WatchKey bullets

Regulatory interaction / filing milestone

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $35 (p=60%)

Bull/Bear spread: +142% / -59%

Vs latest close: Bull +142% · Base +85% · Bear -59%

Scenario probabilities

Bull Target: $46 (p=20%)Base Target: $35 (p=60%)Bear Target: $8 (p=20%)

Commentary

Market sentiment is cautiously optimistic: the analyst median sits materially above the anchor while coverage shows a wide low–high spread, reflecting binary clinical/regulatory risk [#SERP-1] [#SERP-7]. Near-term tone will hinge on upcoming readouts and regulatory signals; positive results could trigger rapid re-rating while adverse outcomes risk sharp drawdown.

As of 2026-01-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Successful near-term clinical readout plus a partnership or expedited regulatory progress drives re-rating toward upper analyst range and rapid revenue ramp.

Bear Case

Negative or ambiguous results, regulatory setbacks, or cash/runway issues leading to dilution and valuation compressing toward analyst low.

Drivers

Scannable catalysts and supporting factors

Interim clinical readout for lead EPIT program
Commercial partnerships and early launch progress

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-20Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$35.38

Range (USD)

$7.87 - $64.74

Count

Query: DBV Technologies SA ADR (DBVT) analyst consensus price target high low average

DBVT | DBV Technologies S.A. ADR Analyst Estimates | MarketWatch
Search result #1
Stock Price Targets. High, $64.74. Median, $45.00. Low, $7.87. Average, $41.13. Current Price, $17.03. Yearly Numbers. Estimates. DBVT will report 2025 earnings ...
Extracted: $64.74, $45.00, $7.87, $41.13, $17.03Open source
DBVT Stock Forecast: Analyst Ratings, Predictions & Price Target ...
Search result #2
Wall Street analysts have set a price target of $31.75, reflecting a 0.00% increase from the current stock price. What is the 2025 price prediction for DBVT?
Extracted: $31.75Open source
What is the current Price Target and Forecast for DBV Technologies ...
Search result #3
The forecasts for DBV Technologies S.A. (DBVT) range from a low of $7.94 to a high of $51. The average price target represents a increase of $112.71 from the ...
Extracted: $7.94, $51.00, $112.71Open source
DBV Technologies SA - American (DBVT) Stock Forecast ... - TipRanks
Search result #4
The average price target is $46.40 with a high forecast of $51.00 and a low forecast of $40.00. The average price target represents a 123.29% change from the ...
Extracted: $46.40, $51.00, $40.00Open source
DBV Technologies S.A. (DBVT) Stock Price, News, Quote & History
Search result #5
Analyst Insights: DBVT. View More. Analyst Price Targets. 8.09 Low. 39.87 Average. 20.78 Current. 50.66 High. Analyst Recommendations. Strong Buy. Buy. Hold.
Open source
DBVT | DBV Technologies S.A. ADR Analyst Estimates & Ratings
Search result #6
Stock Price Target DBVT. High, $64.74. Median, $45.00. Low, $7.87. Average, $41.13. Current Price, $20.78. Related Links: Options · Overview · Research & ...
Extracted: $64.74, $45.00, $7.87, $41.13, $20.78Open source

Scenarios

Bull Target (Scenario probability)

$46 / p=20% prob

Base Target (Scenario probability)

$35 / p=60% prob

Bear Target (Scenario probability)

$8 / p=20% prob

Price $19 as of 2026-05-29

Nearest Scenario: Bear (∆ 59%)

Targets vs latest close: Bull +142% · Base +85% · Bear -59%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-12-31
Regulatory interaction / filing milestone
Potential regulatory filing or major agency interaction for peanut EPIT; assumed window end used for planning purposes [#SERP-3].
Prob 30.00% • Move 60.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Interim clinical readout for lead EPIT program
2026-04-20
Planned interim efficacy/safety readout for lead EPIT program; market likely to reprice on topline binary results (timing estimated) [#SERP-1].
Prob 45% • Move 35% • Priced-in 40%

Long-term Catalysts

Months to a year

Commercial partnerships and early launch progress
2027-01-20
Progress on commercialization or partner deals that could materially increase revenue scale over time; execution and uptake risk remains [#SERP-7].
Prob 25% • Move 120% • Priced-in 20%

Risks

Cash‑runway shortfall leading to dilutive financing
Negative pivotal clinical readout or safety signal
Poor payer coverage or slow commercial uptake
Regulatory delay, limited labeling, or non‑approval

Peers

Symbol	Summary
PFE	Large-cap pharma with established allergy/immunology portfolio and commercialization capability; relevant for partnership and scale dynamics.
SNY	Global immunology presence and allergy treatments; useful comparator for partner-led commercialization and market access.
JNJ	Broad consumer and pharma reach in allergy products and distribution; informative for go-to-market and payer negotiation scenarios.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: DBV Technologies SA ADR (DBVT) analyst consensus price target high low average
Analysis date: 2026-01-20